Comparison of drug‐eluting stents with bare metal stents in unselected patients with acute myocardial infarction
Catheterization and Cardiovascular Interventions2007Vol. 70(1), pp. 1–8
Citations Over TimeTop 10% of 2007 papers
Leon Iri Kupferwasser, Allen M. Amorn, Nikhil Kapoor, Michael S. Lee, Saibal Kar, Bojan Cercek, Suhail Dohad, James Mirocha, James S. Forrester, Prediman K. Shah, Raj Makkar
Abstract
The routine use of DES in acute myocardial infarction is associated with reduced rates of MACE at 12 months vs BMS, despite a higher rate of complex procedures in the DES treated patients. In addition to its anti-restenosis effect, the improved outcome of patients treated with DES may be linked to a more complete revascularization in association with prolonged clopidogrel therapy.
Related Papers
- → Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis(2021)34 cited
- → Same or Different Drug‐Eluting Stent Re‐Implantation for Drug‐Eluting Stent Restenosis: An Assessment Including Second‐Generation Drug‐Eluting Stents(2016)2 cited
- → A History of Prior Bare Metal Stent Restenosis Is Associated with Major Adverse Cardiac Events in Subsequent Bare Metal Stenting of de novo Coronary Lesions(2010)4 cited
- → AS-40: Percutaneous Coronary Interventions with Drug-Eluting Stent Implantation in Cases of Drug-Eluting Stents Restenosis(2009)
- Clinical study of different treatment strategy for AMI patients treated by primary PCI with multi-vessel coronary artery disease(2009)